Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan-Feb;61(1):42-45.
doi: 10.1016/j.hjc.2020.03.002. Epub 2020 Apr 3.

The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design

Affiliations

The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design

Spyridon G Deftereos et al. Hellenic J Cardiol. 2020 Jan-Feb.

Abstract

Objective: Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colchicine in COVID-19 complications prevention.

Methods: Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii. Anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg will be included. Patients will be randomised (1:1) in colchicine or control group.

Results: Trial results will be disseminated through peer-reviewed publications and conference presentations.

Conclusion: GRECCO-19 trial aims to identify whether colchicine may positively intervene in the clinical course of COVID-19. (ClinicalTrials.gov Identifier: NCT04326790).

Keywords: COVID; CRP; Cardiac; Complications; Troponin.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest No conflict of interest exists.

Figures

Image 1
Graphical abstract

Similar articles

Cited by

References

    1. The 2015 ESC Guidelines on the diagnosis and management of pericardial diseases. https://www.ncbi.nlm.nih.gov/pubmed/26547486 PubMed - NCBI. - PubMed
    1. Calkins H., Hindricks G., Cappato R. HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. J Arrhythmia. 2017;33(5):369–409. doi: 10.1016/j.joa.2017.08.001. 2017. - DOI - PMC - PubMed
    1. Hemkens L.G., Ewald H., Gloy V.L. Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis. Heart. 2016;102(8):590–596. doi: 10.1136/heartjnl-2015-308542. - DOI - PubMed
    1. Tardif J.C., Kouz S., Waters D.D. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–2505. doi: 10.1056/NEJMoa1912388. - DOI - PubMed
    1. Zhou F., Yu T., Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. March 2020 doi: 10.1016/s0140-6736(20)30566-3. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data